Abstract：
Acute myocarditis (especially) and pericarditis have been consistently associated with the administration of vaccines against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), generating anxiety in the general population, uncertainty in the scientific community and obstacles to ambitious mass vaccination programs, especially in foreign countries. Like some of its European counterparts, the Portuguese Society of Cardiology (SPC), through its Studies Committee, decided to take a position on some of the most pressing questions related to this issue: (i) How certain are we of this epidemiological association? (ii) What is the probability of its occurrence? (iii) What are the pathophysiological bases of these inflammatory syndromes? (iv) Should their diagnosis, treatment and prognosis follow the same steps as for typical idiopathic or post-viral acute myopericarditis cases? (v) Is the risk of post-vaccine myocarditis great enough to overshadow the occurrence of serious COVID-19 disease in unvaccinated individuals? In addition, the SPC will issue clinical recommendations and offer its outlook on the various paths this emerging disease may take in the future.
摘要：
急性心肌炎（尤其是）和心包炎一直与SARS-CoV-2（严重急性呼吸道综合征冠状病毒2）疫苗的施用有关，在普通人群中产生焦虑，科学界的不确定性和雄心勃勃的大规模疫苗接种计划的障碍，尤其是在国外。像一些欧洲同行一样，葡萄牙心脏病学会（SPC），通过其研究委员会，决定对与此问题有关的一些最紧迫的问题采取立场：（i）我们对这种流行病学关联有多确定？（ii）发生的可能性是多少？（iii）这些炎症综合征的病理生理学基础是什么？（iv）他们的诊断，治疗和预后遵循与典型的特发性或病毒性急性心包炎病例相同的步骤？（v）疫苗后心肌炎的风险是否足以掩盖未接种疫苗的个体中严重COVID-19疾病的发生？此外，SPC将发布临床建议,并对这种新出现的疾病未来可能采取的各种途径进行展望.
